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Abstract
Background: Pre-eclampsia is a pregnancy disorder, characterised by hypertension and multisystem complications
in the mother. The adverse outcomes of pre-eclampsia include severe hypertension, stroke, renal and hepatic injury,
haemorrhage, fetal growth restriction and even death. The optimal time to instigate delivery to prevent morbidity
when pre-eclampsia occurs between 34 and 37 weeks’ gestation, without increasing problems related to infant
immaturity or complications, remains unclear.
Methods/design: The PHOENIX trial is a non-masked, randomised controlled trial, comparing planned early
delivery (with initiation of delivery within 48 h of randomisation) with usual care (expectant management) in
women with pre-eclampsia between 34+ 0 and 36+ 6 weeks’ gestation. The primary objectives of the trial are to
determine if planned delivery reduces adverse maternal outcomes, without increasing the short-term harm to
infants (composite of perinatal deaths or neonatal unit admissions up to infant hospital discharge) or impacting
long-term infant neurodevelopmental status at 2 years corrected age (Parent Report of Cognitive Abilities-Revised).
Discussion: Current practice in the UK at the time of trial commencement for management of pre-eclampsia varies
by gestation. Previous trials have shown that in women with pre-eclampsia after 37 weeks of gestion, delivery is
initiated, as maternal complications are reduced without increasing fetal risks. Prior to 34 weeks of gestation, usual
management aims to prolong pregnancy for fetal benefit, unless severe complications occur, necessitating preterm
delivery. This trial aims to address the uncertainty for women where the balance of benefits and risks of delivery
compared to expectant management are uncertain. Previous trials in this area have been undertaken, but have not
provided a definitive answer, and the research question remains active. The results of this trial are expected to
influence clinical practice internationally, through direct adoption and by incorporation into guidelines in countries
with similar settings.
Trial registration: ISRCTN01879376. Registered on 25 November 2013.
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Background
In the UK, 10–15% of pregnant women develop hyper-
tension in pregnancy, and 2–5% pre-eclampsia. Pre-
eclampsia is a multisystem disorder, characterised by
placental and maternal vascular dysfunction, which is as-
sociated with substantial morbidity and mortality for the
mother and infant. Adverse outcomes of pre-eclampsia
include severe hypertension, stroke, renal and hepatic in-
jury, haemorrhage, fetal growth restriction and even
death [1].
Timely delivery may be indicated to prevent maternal
and infant morbidity. Standard management of pre-
eclampsia involves close monitoring whilst taking into
consideration gestational age, fetal well-being and progres-
sion of maternal disease. When a diagnosis of pre-eclamp-
sia is made at or beyond 37 weeks’ gestation, it is currently
recommended that delivery be induced, since maternal
and fetal risks can be significantly reduced without any ap-
parent added risk associated with the intervention.
Around half (40%) of all pre-eclampsia occurs preterm
(before 37 weeks), and these cases have the most serious
outcomes. Using data from previous pre-eclampsia trials
[2, 3], we have estimated that 33% of women with
pre-eclampsia will present between 34+ 0 and 36+ 6 weeks
of gestation and not require immediate delivery. Delivery
before 34 weeks (meta-analysis of two randomised con-
trolled trials, n = 133) [4] increases neonatal risk (Hya-
line Membrane Disease risk ratio 2.3 [95% confidence
interval, CI 1.39 to 3.81] and necrotising enterocolitis
risk ratio 5.54 [95% CI 1.04 to 29.56]) without sufficient
benefit in maternal outcomes.
The optimal time to instigate delivery to prevent mor-
bidity when pre-eclampsia occurs between 34 and 37
weeks’ gestation, without increasing problems related to
infant immaturity or complications, remains unclear.
Current management involves close surveillance and de-
livery only when evidence of impending serious morbid-
ity becomes apparent (e.g. deteriorating maternal or fetal
condition). As this may be rapid or unexpected, planned
delivery (the proposed intervention) beyond 34 weeks
may be valuable. Neonatal and infant mortality and mor-
bidity (e.g. through respiratory distress syndrome) may,
nonetheless, occur following delivery between 34 and 37
weeks of gestation. However, neurodevelopmental mor-
bidity and risk of growth restriction and death may be re-
duced by early delivery, and adverse events related to
expectant management (including placental abruption,
stillbirth and worsening growth restriction) may be
decreased.
It is highly likely that routine delivery will reduce the
maternal risk, as delivery cures pre-eclampsia. There is,
therefore, a need to compare a policy of planned delivery
between 34+ 0 and 36+ 6 weeks of gestation with that of
expectant management, to evaluate the benefits and
risks for the mother and baby, including assessment of
longer-term neurodevelopmental outcomes.
This aim of this study is to compare planned delivery
with expectant management (usual care) in women with
pre-eclampsia between 34 and 37 weeks’ gestation. This
study arose from a commissioned call by the funder (Na-
tional Institute for Health Research), following develop-
ment of the proposal and choice of important outcomes
by clinicians with patient and public involvement. The
study will be conducted according to the principles of the
Declaration of Helsinki (dated 2008) and all applicable
regulatory requirements. This protocol will be submitted
to an NHS research ethics committee (REC) and the NHS
Trust Research and Development Offices for approval.
Methods/design
Trial objectives
The aim of this study is to determine whether planned
delivery in women with pre-eclampsia between 34+ 0 and
36+ 6 weeks’ gestation reduces maternal adverse out-
comes without substantial worsening of neonatal or in-
fant outcomes, compared with the current practice of
expectant management to 37 weeks’ gestation.
Primary objectives
The primary objectives of the study are:
 To determine if planned early delivery for women
with pre-eclampsia between 34+ 0 and 36+ 6 weeks’
gestation reduces adverse maternal outcomes based
on a composite listed in the fullPIERS [5] paper with
addition of recorded systolic hypertension (systolic
blood pressure of ≥160 mmHg), as highlighted in the
triennial Confidential Enquiry into Maternal Deaths
(2006–8) [6].
 To evaluate the impact of the intervention on
short- and long-term perinatal outcomes. Short-
term outcomes will be assessed by a composite of
perinatal deaths (antenatal or intrapartum stillbirths
or neonatal deaths within 7 days, but not deaths due
to congenital anomaly) or neonatal unit admissions
up to time of infant hospital discharge.
 To determine the impact on infant
neurodevelopmental status at 2 years of age corrected
for prematurity using the Parent Report of Cognitive
Abilities, Revised (PARCA-R) [7] Composite.
Secondary objectives
The secondary objectives of the study are:
 To investigate the effect of the intervention on other
secondary maternal and neonatal short-term
outcomes.
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 To assess the impact of both management strategies
on health-care resource use and quality-adjusted life
years (QALYs)
 To assess the impact of both management strategies
on health economic outcomes
 To evaluate quality of life using questionnaires
immediately after randomisation and at 6 months
and 2 years corrected age.
Trial design
This will be a pragmatic, multicentre, randomised con-
trolled trial of planned delivery versus expectant man-
agement in 900 women with pre-eclampsia between 34+
0 and 36+ 6 weeks of gestation inclusive. The trial will be
conducted in approximately 35 to 45 consultant-led ma-
ternity units across England and Wales. An internal pilot
phase will initially be run, involving six centres over a
period of 6 months to establish whether the procedures
and assessments are conducive to achieving the recruit-
ment and other objectives of the study. Recruitment is
anticipated to take 36 months based on an assumption
that each centre will on average recruit 1.5 women per
month, with some allowance for unforeseen events and
centres recruiting slower than expected. The study, in-
cluding set-up, pilot phase, completion of mother and
infant follow-up and reporting, is anticipated to take 72
months to complete. If the processes are shown to work
in the internal pilot phase, recruitment to the main trial
will proceed with no break and data from the internal
pilot phase will be analysed together with the main trial
data collected. The internal pilot will aim to recruit a
total of 41 women by the end of month 6. Progression
criteria (internal pilot into main trial) will be recruitment
in the pilot study of at least 75% of target (31 women or
more) with loss to follow-up of no more than seven
women.
Selection and withdrawal of participants
Inclusion criteria
Women who meet the following criteria will be eligible
for enrolment into the study:
 Pregnancy of between 34+ 0 and 36+ 6 weeks of
gestation inclusive
 Pre-eclampsia defined by the International Society
for the Study of Hypertension in Pregnancy 2014 [8]
as (1) diastolic blood pressure ≥90 mmHg (twice, ≥4
h and <1 week apart) or (2) diastolic blood
pressure ≥110 mmHg on one occasion [9] and one
or more of the following: (i) proteinuria (≥0.3 g/day
by 24-h urine collection or ≥ 30 mg/mmol by spot
urinary protein creatinine ratio), (ii)
thrombocytopenia (platelet count < 150 × 109/L), (iii)
renal insufficiency (creatinine ≥90 μmol/L), (iv)
impaired liver function (alanine transaminase or
aspartate transaminase >70 IU/L), (v) fetal growth
restriction (Estimated fetal weight EFW <10th
centile confirmed by ultrasound); or superimposed
pre-eclampsia
 Singleton or dichorionic diamniotic twin pregnancy
 Viable fetus
 Aged 18 years or over at the time of screening
 Able to give written informed consent
Women with any other co-morbidity (including pre-
existing hypertension, diabetes etc.) or having had a
previous caesarean section or with the fetus in any pos-
ition will be eligible.
Exclusion criterion
Women will be excluded from participation in the study
if a decision has already been made to deliver within the
next 48 h.
Recruitment, eligibility and consent
Members of the research team will provide a full verbal
explanation and written description of the trial to
women who meet the inclusion criteria (as above). The
woman will be given sufficient time to consider the infor-
mation, and to decide whether she will participate in the
trial. Written informed consent will be sought from the
woman and taken by an appropriately trained doctor.
Study periods
A woman’s participation in the study may be from 34
weeks’ gestation until their child reaches 2 years of age
corrected for prematurity, a maximum duration of 28
months.
Withdrawal of participants
Women will be able to withdraw their consent at any
time without giving a reason. Withdrawal from the study
will not affect their (or their baby’s) ongoing care and
there will be no requirement for any study-related
follow-up safety assessments. The intervention may be
discontinued if their clinician feels it is in the baby’s best
interests. For a woman allocated to the expectant man-
agement group, the attending clinician will make a deci-
sion for delivery based on the National Institute for
Health and Care Excellence (NICE) guidelines, with de-
livery planned at 37 weeks’ gestation. If clinical needs
dictate delivery prior to 37 weeks’ gestation, this will not
constitute withdrawal from the trial allocation. For a
woman allocated to the planned delivery group, if the
woman should decide that she does not wish to proceed
with the planned delivery and instead chooses to con-
tinue to be monitored by her attending clinician, this
will not constitute withdrawal from the study. There is
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no requirement to replace women who do not complete
the study or need to be delivered prior to their planned
delivery date.
Assessment of outcomes
Outcomes will be recorded on the web-based database after
a review of case notes by trained researchers after the dis-
charge of the mother and baby. Confirmation of maternal
outcome data (to include occurrence or not of the primary
outcome) will be undertaken with an additional sign-off by
the site’s principal investigator for each participant.
Co-primary outcomes
Primary short-term maternal outcome
 Composite of maternal morbidity of fullPIERS [5]
outcomes with the addition of recorded systolic
blood pressure ≥160 mmHg (with or without
medication) post-randomisation.
Primary short-term perinatal outcome
 Composite of perinatal deaths (antenatal or
intrapartum stillbirths or deaths within 7 days of
delivery but not deaths due to congenital anomalies) or
neonatal unit admissions (physical separation of baby
from the mother) prior to infant hospital discharge.
Primary long-term infant outcome
 PARCA-R composite score for neurodevelopment at
2 years of age corrected for prematurity [7].
Secondary outcomes
Secondary maternal outcomes will include assessments of:
 Individual components of the composite primary
outcome, as number of women with one or more of
the following: eclampsia, Glasgow coma scale <13,
stroke, hypertensive encephalopathy, posterior
reversible encephalopathy, cortical blindness, retinal
detachment, myocardial infarction, intubation other
than for a caesarean section, pulmonary oedema,
ionotropic support, saturation <92%, 50% FiO2 for
> 1 h, infusion of a third parenteral antihypertensive,
platelets <50 × 109/L, disseminated intravascular
coagulation, thrombotic thrombocytopenic purpura,
haemolytic uraemic syndrome, acute fatty liver of
pregnancy, hepatic dysfunction, haematoma or
rupture, severe acute kidney injury (creatinine
> 150 μmol/L or > 200 μmol/L in chronic kidney
disease, dialysis, transfusion of blood products)
 Severe hypertension post-randomisation (systolic
blood pressure ≥160 mmHg with or without
medication on at least one occasion) recorded in
written or electronic notes and measured by
health-care professionals in clinical care
 Use of anti-hypertensive drugs recorded in written
or electronic notes prescribed by health-care
professionals in clinical care
 Progression to severe pre-eclampsia, defined as
systolic blood pressure ≥160 mmHg, platelet count
< 100 × 109/L and abnormal liver function enzymes
(ALT or AST > 70 IU/L)
 Estimated fetal weight (on ultrasound scan) <10th
centile post-enrolment
 Absent or reversed end diastolic flow (on umbilical
artery Doppler)
 Time and mode of onset (spontaneous, induced or
pre-labour caesarean section) and mode of delivery
(spontaneous vaginal delivery, assisted vaginal
delivery or caesarean section)
 Confirmed thromboembolic disease requiring
anticoagulation up to post-natal discharge
 Confirmed sepsis (positive blood or urine cultures)
up to post-natal discharge
 Primary and additional indications for delivery in the
expectant management arm: maternal hypertension
not controlled by maximal therapy, biochemical
abnormality, haematological abnormality, fetal
compromise on ultrasound scan, fetal compromise
on cardiotocography, severe maternal symptoms, 37
weeks of gestation or specified other
 Placental abruption
Secondary perinatal outcomes will include assess-
ments of:
 Stillbirth post-randomisation
 Neonatal death prior to hospital discharge
 Admissions to neonatal unit
 Number of nights in each category of care (intensive,
high dependency, special, transitional and normal)
 Total number of nights in hospital
 Birth weight (g)
 Customised/population birth weight centile
 Birth weight <10th and <3rd customised/population
centile
 Gestational age at delivery
 Apgar score at 5 min post-birth
 Umbilical arterial and venous pH (and base excess)
at birth
 Need for supplementary oxygen prior to discharge
 Number of days when supplemental oxygen is
required
 Need for ventilation support (continuous positive
airway pressure, high flow or endotracheal
ventilation)
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 Abnormal cerebral ultrasound scan
 Confirmed sepsis (positive blood or cerebrospinal
fluid cultures)
 Necrotising enterocolitis (Bell’s stage 2 and 3)
 Seizures (confirmed by electroencephalography
or requiring anticonvulsant therapy)
 Encephalopathy grade (worst at any time: mild,
moderate or severe)
 Hypoglycaemia (blood glucose < 2.6 mmol/L on two
or more occasions)
 Other indications and main diagnoses resulting in
neonatal unit admission
 Exclusively breastfed at discharge from the
neonatal unit
Secondary long-term maternal outcomes will include
assessments of:
 Quality of maternal physical and mental health
using the validated SF-12v2® questionnaire when the
infant is 6 months and 2 years of age corrected for
prematurity.
Secondary health economic and quality of life out-
comes will include assessments of
 Quality of life using the validated quality
of life questionnaire EQ-5D-5 L [10] immediately
after randomisation, at 6 months and when
the infant is 2 years of age corrected for
prematurity
 Hospital attendances, nights and diagnostic tests
from randomisation until delivery
 Cost of delivery
 Cost of neonatal care (hospital admissions, surgery
and diagnostic tests)
 Retrospective 6-month health and social care
use by mother and infant at 6 months and
2 years
 EQ-5D-5 L [10] for the calculation of maternal
QALYs
Trial procedures
The study procedures are shown in Fig. 1.
Informed consent
Written consent will be sought from the woman only
after she has been given a full verbal explanation and
written description of the trial (via the participant infor-
mation leaflet; Additional file 1). Women who do not
speak English will be approached only if an adult inter-
preter is available. Relatives may not interpret. Introduc-
tory verbal and written information should be offered to
all potentially eligible women with pre-eclampsia at the
study’s recruiting centres. Written informed consent will
be given using an informed consent form (Additional
file 2) completed, signed and dated by the woman
(with a countersignature by an interpreter where required)
and signed by the person who obtained informed consent,
who will be the principal investigator or another study
doctor with delegated authority. After written informed
consent has been obtained, a member of the research
team will enter the baseline data onto the online database
and perform randomisation, communicating the results dir-
ectly to the woman. At all stages, it will be made clear to
the woman that she is free to withdraw from the trial at
any time without the need to provide any reason or explan-
ation. Participants will be made aware that this decision will
have no impact on any aspect of their continuing care.
The management of pregnant women whilst in hos-
pital should be in accordance with the NICE guidelines
for the management of hypertension in pregnancy [11].
Delivery will be in accordance with standard procedures
but will most likely be through induction with prosta-
glandins, unless contraindicated. All options should be
discussed with the pregnant woman and her needs and
preferences taken into account.
Otherwise, women will be managed as follows.
Intervention (planned delivery) group
The intervention is planned delivery with minimal delay
(with initiation of delivery within 48 h of randomisation
to allow for steroid use and neonatal cot availability).
Use of corticosteroids will be at the discretion of the in-
dividual clinician as indicated in the NICE guidelines.
Postnatal care should follow NICE guidelines [11, 12].
Control (expectant management) group
Usual care is expectant management of pregnancy, as in-
dicated by NICE guidelines and delivery at 37 weeks of
gestation or sooner as clinical needs dictate. The NICE
guidelines cover care on admission to hospital, treat-
ment, measurement of blood pressure, testing for pro-
teinuria and other parameters depending on whether the
woman has mild or moderate hypertension.
If the woman has mild hypertension (blood pressure
140/90 to 149/99 mmHg), care would be as follows:
 Admission to hospital
 Measure blood pressure at least 4× a day
 No treatment of blood pressure
 No repeat quantification of proteinuria
 Blood test monitoring twice a week to determine
kidney function, electrolytes, full blood count,
transaminases and bilirubin.
If the woman has moderate hypertension (blood pres-
sure 150/100 to 159/109 mmHg), care would be as for
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mild hypertension with the addition of the following
assessments:
 Administration of oral labetalol to keep
diastolic blood pressure between 80 and
100 mmHg and systolic blood pressure
< 150 mmHg
 Blood test monitoring thrice a week to determine
kidney function, electrolytes, full blood count,
transaminases and bilirubin.
Time of delivery: adherence to protocol
Following randomisation to either the planned delivery
group (intervention) or expectant management group
(control), the time of the onset of planned delivery (first
method for induction of labour or time of planned cae-
sarean section along with the indication) or onset of
spontaneous labour will be recorded for all women. This
will enable the monitoring of adherence to the protocol
for both study groups so that protocol deviations can be
identified and investigated.
Sample size
The sample size for the PHOENIX study is calculated
on the ability to observe a clinically significant risk re-
duction in the primary short-term maternal composite
outcome of maternal morbidity and recorded systolic
blood pressure of ≥160 mmHg, measured after
Fig. 1 Schedule of participant enrolment, interventions and assessments in the trial. PARCA-R Parent Report of Cognitive Abilities, Revised, SAE serious
adverse event. 1 Screening to be conducted of all women suspected of being eligible for the study. 2 Delivery to be commenced within 48 hours of
randomisation for women randomised to the planned delivery group. 3 Eligibility for study to be assessed from blood pressure recorded at the time
the diagnosis of pre-eclampsia. 4 Blood systolic pressure reading within the 48 hours prior to randomisation to be recorded. 5 Highest systolic blood
pressure recorded between randomisation and delivery to be recorded. 6 Highest systolic blood pressure recorded between delivery and discharge to
be recorded. 7 Haematology and/or Biochemistry results that contributed to diagnosis of pre-eclampsia to be recorded. 8 The most
recent Haematology and/or Biochemistry results prior to randomisation to be recorded. 9 Abnormal Haematology/ Biochemistry results
from randomisation to discharge to be recorded at discharge. 10 Serious Adverse Events (SAEs) to be recorded from randomisation to
post-natal discharge. Only unexpected SAEs to be reported. 11 Brief details of anti-hypertensive and medication for induction will be
recorded; all other concomitant medication will only be recorded in the event that an unexpected Serious Adverse Event is reported. 12
EQ-5D-5L[10] to be given to the participant to complete immediately after randomisation
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randomisation. It is also powered to ensure that a clinic-
ally relevant effect size can be detected for the short-
and long-term perinatal co-primary outcomes.
Superiority hypothesis for the primary short-term maternal
outcome
Based on data from the PELICAN study [2], 49 of 115
women with suspected pre-eclampsia (42.6%, 95% CI
33.4% to 52.2%) enrolled between 34+ 0 and 36+ 6 weeks
of gestation developed maternal morbidity and systolic
hypertension of ≥160 mmHg. Therefore, assuming an
expected adverse maternal outcome incidence of 43% in
the control group (expectant management), a sample
size of 850 women will be needed to demonstrate a rela-
tive risk reduction of 25% to 32.25% (deemed clinically
significant) with a two-sided 5% significance level and
90% power in the planned delivery group. Taking into
account a 5% loss of women in the follow-up, the overall
target sample size for the study is 900 women (450 per
group).
Non-inferiority hypothesis for the neonatal outcomes
A sample size of 850 women will result in approximately
860 live births (assuming 1 in 80 pregnancies are twin
pregnancies). The PELICAN study [2] reported that a
composite of perinatal death or any neonatal admission
occurred in 27 of 115 infants (23.5%, 95% CI 16.1% to
32.3%). Assuming a composite adverse neonatal out-
come incidence of 24% in the control group (expectant
management), a sample size of 860 (430 per group) will
achieve 93% power to detect a non-inferiority margin of
a difference in incidence of no less than 10% (judged to
be clinically relevant) and 78% power to detect a margin
of no less than 8%.
To examine the component of perinatal death specific-
ally, using Office for National Statistics data for all ba-
bies born in England and Wales in 2013, it is estimated
that 1.6% (585/36,939) of all preterm births were peri-
natal deaths (stillbirth and early neonatal) [13]. A similar
incidence is expected in women with pre-eclampsia as
those deaths prevented by increased surveillance would
be offset by pre-eclampsia associated co-morbidities of
fetal growth restriction and placenta abruption. Thus,
for the component of perinatal death, assuming a con-
trol group incidence of 1.5%, a sample size of 430 in
each group would achieve 90% power to detect a
non-inferiority margin of a difference in incidence of no
less than 2.7%. For the component of neonatal unit ad-
mission, assuming a control group incidence of 21%, a
sample size of 430 in each group will achieve 90% power
to detect a non-inferiority margin of a difference in inci-
dence of no less than 9%.
Assuming a loss to follow-up at 2 years of 20%, we
should obtain long-term outcomes for approximately
690 infants (345 per group assuming no difference in
the loss to follow-up between the groups). The PARCA-
R questionnaire [7] provides a composite score for neu-
rodevelopment with a standardised mean of 100 and
standard deviation of 15. With a one-sided significance
level of 2.5%, under a non-inferiority hypothesis, a sam-
ple size of 345 in each group achieves 94% power to de-
tect a non-inferiority margin of a difference in the mean
PARCA-R score of no less than 4 points (1/4 of a stand-
ard deviation). A margin of no less than 3 points can be
detected with 75% power. Considering the results from
the INFANT trial [14] of over 46,000 higher risk women
with babies of over 35 weeks’ gestation, the original
power calculation was revised. Using a revised standard
deviation of 34, a sample size of 345 in each group
will detect a non-inferiority margin of a difference in
the mean PARCA-R score of no less than 9 points
(1/4 of a standard deviation) with 94% power. A mar-
gin of no less than 7 points can be detected with 77%
power.
In summary, a sample size of 900 women will have at
least 90% power to detect: (1) a relative risk reduction of
25% (from 43% to 32%) in the primary maternal com-
posite outcome, (2) a non-inferiority margin of a differ-
ence in the incidence of the primary short-term
perinatal outcome of no less than 10% (from 24%) and
(3) a non-inferiority margin of a difference in the mean
2-year PARCA-R score of ≥9 points.
Randomisation
The allocation ratio for the intervention (planned deliv-
ery) to usual care (expectant management) will be 1:1.
Randomisation will be managed via a secure web-based
randomisation facility hosted by MedSciNet with a tele-
phone back-up available at all times. A minimisation al-
gorithm will be used to ensure balance between the
groups with respect to the collaborating hospital, single-
ton or twin pregnancies, severity of hypertension in the
48 h prior to enrolment (highest systolic blood pressure
with or without medication: ≤149 mmHg, 150–159
mmHg, ≥160mmHg), parity (delivery of a baby past 24
weeks' gestation), previous caesarean sections and gesta-
tional age at randomisation (34, 35 or 36 weeks).
MedSciNet will write the randomisation program
and hold the allocation code. Following randomisa-
tion, the obstetrician will then arrange for delivery or
ongoing expectant management as indicated by the
randomisation.
Masking
Due to the nature of this study, masking of clinicians,
nursing staff and participants is not possible.
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Data collection
Data collection before postnatal discharge
Much of the outcome data for this trial are routinely re-
corded clinical items that can be obtained from the clin-
ical notes or local hospital results system. No additional
blood or tissue samples are required for this study.
Women will be asked to complete the EQ-5D-5 L [10]
questionnaire at the time of randomisation, which usu-
ally takes fewer than 5 minutes.
Data collection after discharge
Questionnaires will be sent to all participants at 6
months post-delivery and 2 years of age corrected for
prematurity. The 6-month and 2-year questionnaires will
collect the following data: EQ-5D-5 L [10], SF-12v2® [15]
and maternal and infant health and social care use after
their hospital discharge. In addition, the PARCA-R ques-
tionnaire [7] will be collected at 2 years.
Data processing
All hospital trial data will be collected using bespoke
electronic case report forms and entered directly into
the study’s electronic database by the centre’s research
staff. Data will be stored by single-entry only and at the
point of entry, the data will undergo a number of valid-
ation checks to verify the validity and completeness. An
additional sign-off of the maternal outcomes data will be
performed by the site’s principal investigator for each
participant. Follow-up questionnaires returned by post
or completed by the mother on-line will also undergo a
number of validation checks at the point of entry.
Assessment of safety
A Data Monitoring Committee (DMC) will be estab-
lished to ensure the wellbeing of study participants. The
DMC will periodically review study progress and out-
comes as well as reports of unexpected serious adverse
events (SAEs). The DMC will, if appropriate, make rec-
ommendations to the Trial Steering Committee (TSC)
regarding continuance of the study or modification of
the study protocol.
Adverse events
An adverse event is any untoward medical occurrence in
a participant. It does not necessarily have to have a
causal relationship with this intervention. Due to the
high incidence of adverse events routinely expected in
this patient population (e.g. abnormal laboratory find-
ings, new symptoms etc.), only those adverse events
identified as serious will be recorded for the trial.
Serious adverse events
An SAE is any untoward medical occurrence that:
 results in death
 is life-threatening
 requires participant hospitalisation or prolongation
of existing hospitalisation
 results in persistent or a significant disability or
incapacity
 is a congenital anomaly or birth defect
 is an important medical event
Expected SAEs
Expected SAEs are those events that are expected in the
patient population or as a result of the routine care or
treatment of a patient. The following events are ex-
pected in women with pre-eclampsia and their infants
and as such do not require reporting as SAEs.
Expected maternal SAEs
 hepatic dysfunction
 hepatic haematoma or rupture
 coma or impaired consciousness (Glasgow coma
score <13)
 cortical blindness
 reversible ischaemic neurological deficit
 retinal detachment
 acute renal insufficiency or failure
 postpartum haemorrhage requiring transfusion or
hysterectomy
 platelet count <50,000
 severe uncontrolled hypertension
 myocardial ischaemia or infarction
 severe breathing difficulty
 pulmonary oedema
 sepsis
 admission to hospital for pre-eclampsia (if managed
as an outpatient)
Although it is known that maternal death and strokes
can occur in women with pre-eclampsia, they should
still be reported as an SAE.
Expected infant SAEs
 perinatal death (unless unexpected in this
population)
 congenital anomaly
 low birth weight
 reversed end diastolic flow
 requirement for supplemental oxygen or ventilation
support
 intraventricular haemorrhage
 sepsis confirmed by positive cerebrospinal fluid or
blood cultures
 necrotising enterocolitis
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 seizures
 encephalopathy
 hypoglycaemia
Although it is known that neonatal death and stillbirth
can occur in infants born to women with pre-eclampsia,
they should still be reported as an SAE.
Unexpected SAEs
An unexpected SAE is any event that meets the defin-
ition of an SAE and is not detailed in the list above as
expected. The following unexpected SAEs must be
reported:
 maternal death
 maternal stroke
 stillbirth
 neonatal death
Safety reporting procedures
SAE recording
All SAEs (as described above) will be recorded from ran-
domisation to the post-natal discharge from hospital of
mother and baby.
Unexpected SAE reporting
Only unexpected SAEs will be reported. These will be
followed up until the post-natal discharge of mother and
baby from acute hospital care. Unexpected SAEs for
both the mother and infant will be recorded and re-
ported to the Clinical Trials Unit of the National Peri-
natal Epidemiology Unit (NPEU) within 24 h of research
staff at the site becoming aware of the event. An SAE
occurring to a participant will be reported to the REC,
which gave a favourable opinion of the study, if, in the
opinion of the chief investigator, the event was related
(resulted from the administration of any of the research
procedures) and unexpected in relation to those proce-
dures. Reports of related and unexpected SAEs will be
submitted within 15 working days of the chief investiga-
tor becoming aware of the event, using the Health Re-
search Authority’s form for reporting an SAE. All
reported SAEs will be regularly reviewed by the DMC
throughout the study. The chief investigator will inform
all investigators concerned of relevant information that
could adversely affect the safety of participants.
Direct access to source data and documents
Direct access to source data and documents (including
hospital records and notes, clinical charts, laboratory re-
ports, pharmacy records and test reports) will be granted
to authorised representatives from the NPEU Clinical
Trials Unit, the sponsor and host organisations to permit
study-related monitoring, audits and inspections.
Statistical analysis
The primary analysis for all maternal outcomes will be
by intention to treat with participants analysed in the
groups to which they are assigned regardless of protocol
non-compliance. The primary analyses for all perinatal
and infant outcomes will be by intention to treat and
per protocol, since the hypothesis under examination for
these outcomes is a non-inferiority hypothesis. The
intention-to-treat analysis will include data from all
women who discontinue the intervention for any reason
and data from all women who withdraw, up to the point
of their withdrawal (after which no further data will be
collected). The per-protocol analysis will exclude babies
of women who do not receive the allocated intervention
as per protocol. Non-inferiority will be concluded if the
results from both populations are consistent with each
other. If women in the expectant management arm are
delivered prior to 37 weeks’ gestation due to clinical need
(i.e. with new indications for delivery by NICE guidelines
[11, 12]), this will not be considered a protocol devi-
ation. A sensitivity analysis will also be carried out ex-
cluding babies of women randomised to the planned
delivery arm where initiation of delivery is more than 96
h post-randomisation. This is to allow for clinical (e.g.
steroid administration) and logistical (e.g. availability of
labour ward bed or neonatal unit cot) delays.
All outcomes will be analysed adjusting for minimisa-
tion factors (as listed above) at randomisation [16] where
possible. Binary outcomes will be analysed using log bi-
nomial regression models. If the model does not con-
verge, log Poisson regression models with robust
variance estimation will be used [17]. Results will be pre-
sented as adjusted risk ratios with associated CIs. The
site will be treated as a random effect in the model, and
all other factors as fixed effects. For continuous out-
comes, differences in means and associated CIs will be
estimated using linear regression models assuming the
residuals are normally distributed. Should this assump-
tion be considered unmet, quantile regression methods
will be used. For all primary outcomes, 95% CIs will be
presented. For the analysis of perinatal outcomes, the
adjusted analysis will also account for the correlation of
outcomes in twins included in the trial by treating these
as random effects in the model.
The frequency and content of any interim analyses, in-
cluding any stopping guidelines, will be determined by
an independent DMC and documented in the DMC’s
charter.
Further details of the short-term outcomes can be
found in the statistical analysis plan (Additional file 3).
A statistical analysis plan for the 2-year follow-up ana-
lysis is currently in development.
The loss to long-term follow-up is expected to be
around 20% to 30% and to be associated with poor
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outcomes and lower socioeconomic status. Babies for
whom no 2-year follow-up data are received will be
compared to babies with 2-year data on demographic
and clinical characteristics as well as short-term
outcomes.
Economic evaluation
An economic evaluation from the perspective of the Na-
tional Health Service (NHS) and personal social services
will be conducted alongside the main trial. Data on
health and social care resource utilisation will be col-
lected using patient administration systems, maternity
and neonatal databases, and logs of tests and proce-
dures, together with data from questionnaires adminis-
tered at 6 months and 2 years, which capture health and
social care resource use for mother and child in the pre-
vious 6 months. Health and social care services will be
costed using national published sources (NHS reference
costs and Unit Costs of Health and Social Care, Personal
Social Services Research Unit, British National For-
mulary). QALYs for the mother will be calculated
from EQ-5D-5 L [10] utility scores collected at base-
line, 6 months and 2 years and the SF-12v2® [15]
questionnaire also at 6 months and 2 years. Differ-
ences in infant mortality between the two groups will
be captured by assuming full health up to 2 years for
surviving infants. The final results of the economic
evaluation analyses will be expressed as the mean in-
cremental cost per mean QALY gained from baseline
until the 2-year follow-up. Costs and QALYs in the
second year will be discounted in line with NICE
guidance [18]. As the analysis will be undertaken after
the 2-year follow-up, a full health economic analysis
plan, linking with the 2-year statistical analysis plan,
is currently in development.
End of trial
The PHOENIX trial has two phases: an intervention
phase and a follow-up phase. The end of the interven-
tion phase will be when the last participating mother
and infant have been discharged from hospital. For regu-
latory purposes, the end of the study is defined as the
date when the study database is locked. An end of study
declaration will be made to the approving REC within 3
months of this date.
Early cessation
Based on interim data on the trial’s outcomes, adverse
event data, accumulating evidence from other trials and
any other evidence from relevant studies, the DMC will
inform the TSC if, in its view, there is proof beyond rea-
sonable doubt that the data indicate that the trial should
be terminated. This will apply if any part of the proto-
col under investigation is either clearly indicated or
contra-indicated, either for all infants or for a particular
subgroup of trial participants. A decision to inform the
TSC of such a finding will, in part, be based on statis-
tical considerations. Appropriate proof beyond reason-
able doubt cannot be specified precisely. A difference of
at least 3 standard errors in the interim analysis of a
major outcome may be needed to justify halting or
modifying the study prematurely, for the superiority
hypothesis.
Participant confidentiality, data handling and record
keeping
Overall responsibility for ensuring that each participant’s
information is kept confidential will lie with the study
sponsor. All paper documents will be stored securely
and kept in strict confidence in compliance with the
Data Protection Act (1998) and the General Data Pro-
tection Regulation. Data entered onto electronic case re-
port forms will be automatically transferred for storage
in an electronic database held by MedSciNet on behalf
of the sponsors. Participants will be identified only by a
study-specific number and their initials. The participant’s
name and any other identifying details will be stored in a
separate database also held by MedSciNet on behalf of
the sponsors. The databases will be linked only by the
participant’s study number. This identifiable information
will be collected and retained with the participant’s ex-
plicit consent to enable follow-ups to be undertaken.
After the study has completed and the reports published,
the data will be archived in a secure physical or elec-
tronic location with controlled access.
Electronic files will be stored on a file server that has
restricted access. The server is in a secure location and
access is restricted to a few named individuals. Author-
isation to access restricted areas of the NPEU Clinical
Trials Unit network is as described in the unit’s security
policy. Data will be processed on a workstation by
authorised staff. All paper documents will be stored se-
curely and kept in strict confidence in compliance with
the Data Protection Act (1998) and the General Data
Protection Regulation and all trial data will be stored in
line with the Medicines for Human Use (Clinical Trials)
Amended Regulations 2006. Due to the nature of preg-
nancy research, data will be kept for a period of no fewer
than 25 years to allow follow-ups on health-related is-
sues that may become relevant. All personal data will be
held securely at all times and will not be used for any
other purpose.
The dataset will be available to appropriate academic
parties on request from the chief investigator in accord-
ance with the data-sharing policies of King’s College
London and the NPEU Clinical Trials Unit, with input
from the co-investigator group where applicable.
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Retention of personal data
Personal data will be used to contact the participant, to
thank them for participating in the study, to facilitate
the follow-ups at 6 months and 2 years of age, to
co-ordinate the follow-ups and to disseminate the results
of the study to participants.
Data security
An IT security risk assessment of MedSciNet will be
undertaken by the sponsor. Prior to recruitment com-
mencing, data-sharing agreements will be produced to
ensure that all study data are captured and stored as
per the sponsor’s security policy and in compliance
with all UK data storage requirements. A similar risk
assessment and data-sharing agreement will also be
produced to ensure EQ-5D-5 L data captured via the
EuroQol website are captured, stored and transferred
to the MedSciNet database as per the sponsor’s se-
curity policy.
Quality control and assurance
Site initiation and training
The site principal investigator and a local research mid-
wife or nurse, or their delegates, from each recruiting
centre will be fully trained in the protocol and data col-
lection procedures. They will then be responsible for de-
livering this training to all relevant site staff to make
sure that they are conversant with the trial’s procedures
prior to opening their centre for recruitment. The site
research team will also promote the trial so that the
necessary recruitment targets are reached within the
timescale and they will encourage recruitment in their
centre.
Site monitoring and auditing
The site research team will be responsible for the
day-to-day smooth running of the trial at a recruiting
site. The Clinical Trials Unit will monitor recruitment
against targets, provide staff education and training, and
monitor the completeness and quality of collected data.
The study monitor will perform regular visits to all
recruiting centres and will verify the source data for se-
lected participants during these visits.
Throughout the trial, there will be central monitoring,
overseen by the Project Management Group, DMC, TSC
and Quality Assurance team to ensure there is good
communication between the NPEU trial team and site
staff. Trial monitoring will be conducted in accord-
ance with the monitoring plan developed from the
trial-specific risk assessment. The monitor will visit
sites where anomalies are identified through central
monitoring. Sites that are identified as requiring add-
itional support will be visited by a member of the
trial team or the monitor as appropriate to the par-
ticular issues.
The DMC will look regularly at protocol adherence by
site and by trial arm, including randomisation processes
and patterns of allocation.
Risk assessment
A study risk assessment has been performed as part of
the application to receive funding. This risk assessment
will be reviewed at regular intervals during the study
and will be updated as required.
Communication
After REC approval has been obtained, this protocol will
be submitted for publication and will be available for
download via the NPEU website.
Study website
The PHOENIX study website will provide information
on the study to recruiting centres, participants and their
families. Copies of all electronic case report forms, the
study protocol, participant information leaflet and train-
ing literature will be available along with information on
centres participating in the study and contact details for
the coordinating centre. The page for participants will
also have links to other websites that offer advice and
support to people affected by pre-eclampsia.
Discussion
Current practice in the UK at the time of trial com-
mencement for management of pre-eclampsia varies by
gestation. Previous trials have shown that if delivery is
initiated after 37 weeks of gestation for women with
pre-eclampsia, maternal complications are reduced with-
out increasing fetal risks. Prior to 34 weeks of gestation,
usual management is to aim to prolong pregnancy for
fetal benefit, unless severe complications occur that ne-
cessitate a preterm delivery. This trial aims to address
the uncertainty in the balance of benefits and risks of an
earlier delivery compared to expectant management.
Previous trials in this area have been undertaken, but
have not provided a definitive answer, and the research
question remains active. The results of this trial are
highly likely to influence clinical practice internationally,
through a direct impact and through impacting guide-
lines in countries with similar settings.
Trial status
The current PHOENIX protocol is version 3.1 (5 January
2018). The trial opened to recruitment on 29 September
2014. The first participant was recruited on 29 September
2014. All 46 sites (40 NHS Trusts) were opened by 23
January 2018. Recruitment ended on 10 Decem-
ber 2018. Follow-up in progress until last woman and
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infant have been discharged from hospital for short-term
outcomes and to 2 years post-delivery for long-term out-
comes (Additional file 4).
Additional files
Additional file 1: Participant information leaflet. (PDF 1587 kb)
Additional file 2: Consent form. (PDF 238 kb)
Additional file 3: Statistical analysis plan. (DOCX 187 kb)
Additional file 4: SPIRIT 2013 Checklist: Recommended items to address
in a clinical trial protocol and related documents. (DOC 121 kb)
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